Motavizumab

立即咨询

Motavizumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

677010-34-3

MEDI-524

Motavizumab (MEDI-524) 是一种 anti-humanRSV(呼吸道合胞病毒) 单克隆抗体。Motavizumab 可用于高危婴儿的呼吸道合胞病毒感染的研究。

生物活性

Motavizumab (MEDI-524) is an anti-humanRSV(respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virusinfectionin high-risk infants research^[1].

体外研究
(In Vitro)

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription^[2].
Motavizumab inhibits F protein-mediated cell-to-cell fusion^[2].

体内研究
(In Vivo)

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice^[1].

Animal Model:	Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2^[1]
Dosage:	1.25 mg in 0.1 ml of PBS/per mouse
Administration:	Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result:	Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.

Clinical Trial

性状

Liquid

CAS 号

677010-34-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.